TCT 2025: One-Year ENCIRCLE Trial Outcomes
According to the Medical Dialogues Bureau at the TCT Conference 2025 in San Francisco, USA, percutaneous transseptal mitral valve replacement (TMVR) with the SAPIEN M3 System has shown significant benefits.
The results from the ENCIRCLE trial, presented by Dr. John Webb, indicate that TMVR with the SAPIEN M3 System reduces mitral regurgitation (MR) severity, improves functional status and quality of life, and achieves low mortality and heart failure hospitalization rates at one year.
The ENCIRCLE trial is a pivotal study evaluating outcomes of a fully percutaneous, transseptal TMVR system in patients with symptomatic MR who are not suitable candidates for surgery or other commercially available transcatheter treatment options.
Results from the ENCIRCLE trial presented by Dr. John Webb on behalf of the ENCIRCLE investigators at TCT 2025.
Author's summary: TCT 2025 presents reduced mortality with TMVR.
More News
- The billionaire loophole: How Canada’s tax system fuels inequality
- “Quezon” and the unease of history
- Quezon, genealogical proximity, and change
- The real energy vampires are hiding in plain sight | PODIUM
- How the Crow flies, and more | BIDLACK
- China’s Coming Small Wars | Center for International Maritime Security
- Lebanon and Syria October 2025: A Snapshot